Severity Variant rs10191329 has no Effect on Prognostic Factors, Serum GFAP Levels and Cognitive Impairment in Turkish Patients With Multiple Sclerosis (P5-18.009)

Q: What does this research mean for the field?

The rs10191329*A allele has no significant effect on prognostic factors, serum GFAP levels, or cognitive impairment in Turkish patients with multiple sclerosis. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Zeynep Kaya Dogu; Songul Purtuloglu; Yunus Terzi; Zerrin Celik; Birsen Can Demirdöğen; Eda Derle ciftci; Munire Kilinc Toprak

doi:10.1212/wnl.0000000000215436

June 9, 2026Neurology

Severity Variant rs10191329 has no Effect on Prognostic Factors, Serum GFAP Levels and Cognitive Impairment in Turkish Patients With Multiple Sclerosis (P5-18.009)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To examine the impact of the rs10191329*A allele on prognostic factors, serum GFAP levels, and cognitive decline in Turkish patients with multiple sclerosis.
Case-control study of Turkish multiple sclerosis patients
Assessment of serum GFAP levels and cognitive impairment measures
Comparison of prognostic factors between rs10191329 allele carriers and non-carriers.
No significant effects of rs10191329 on prognostic factors observed.
Serum GFAP levels did not differ between allele carriers and non-carriers.
Cognitive impairment showed no association with the presence of rs10191329 variant.

Implication

Case-control study investigates rs10191329's impact on cognitive decline in Turkish MS patients, suggesting no significant effects.

Abstract

Our case-control study investigated the effect of carrying the rs10191329*A allele on prognostic factors, serum GFAP (sGFAP) levels and cognitive decline in Turkish multiple sclerosis (MS) patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dogu et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056001 https://doi.org/10.1212/wnl.0000000000215436

View Full Paper

Ask AI

Bookmark

Share

Severity Variant rs10191329 has no Effect on Prognostic Factors, Serum GFAP Levels and Cognitive Impairment in Turkish Patients With Multiple Sclerosis (P5-18.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Severity Variant rs10191329 has no Effect on Prognostic Factors, Serum GFAP Levels and Cognitive Impairment in Turkish Patients With Multiple Sclerosis (P5-18.009)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading